Beclin 1在乳腺浸润性导管癌组织中的表达  

The Expression of Beclin 1 in Invasive Ductal Carcinoma of the Breast

作　　者：姚维深[1] 张旭[2] 刘艳[1] 周国华[1] 

机构地区：[1]南方医科大学附属南海医院胸外科,广东佛山528200 [2]中山大学肿瘤防治中心胸外科,广东广州510060

出　　处：《河北医学》2014年第7期1057-1061,共5页Hebei Medicine

基　　金：广东省佛山市医学类科技攻关项目;(编号:201208135)

摘　　要：目的:探讨Beclin l在乳腺浸润性导管癌中的表达及临床意义。方法:免疫组织化学EnVision法、RT-PCR法和Western blot法检测50例乳腺浸润性导管癌及相应癌旁组织Beclin 1表达,分析其临床意义。结果:三种方法联合检测发现癌组织中Beclin 1阳性率低于癌旁组织,癌组织中Beclin 1相对表达量也低于癌旁组织;癌组织中Beclin 1表达与患者病理分级、临床分期和淋巴结转移情况有关(P<0.05),与患者年龄、绝经状况及乳头侵犯状况无关(P>0.05)。结论:Beclin l在乳腺浸润性导管癌中存在缺失表达或低表达,并与乳腺癌的发生、发展相关。Objective：To investigate the expression of Beclin 1 in invasive ductal carcinoma （ IDC ） of the breast, and to evaluate the clinical implications.Method： Immunohistochemical, RT-PCR and Western blot methods were used to determine the expression of Beclin 1 in 50 cases of IDC and nearby mucosa of the carcinoma .The relationship between the gene expression and clinicopathological features were analyzed .Result：The lost and negative expression rates of Beclin 1 in IDC was higher than nearby mucosa of the carcinoma.The expression of Beclin 1 were negatively correlated with the clinicopathological features , tissue types and neck lymph node metastasis in IDC （P〈0.05）, and no correlated with ages, menopausal status and nipple infringement status （ P〉0.05）.Conclusion： There was a common lost and negative expression rates of Beclin 1 in IDC.The expression of Beclin 1 may relate to the tumorigenesis and development of the invasive ductal breast cancer .

关 键 词：乳腺浸润性导管癌 BECLIN 1 免疫组织化学 RT-PCR WESTERN BLOT 

分 类 号：R737.9[医药卫生—肿瘤]